GE MEDICAL SYSTEMS

πŸ‡«πŸ‡·France
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

Phase 3
Terminated
Conditions
Coronary Artery Disease
Interventions
Drug: iodixanol
First Posted Date
2006-07-04
Last Posted Date
2019-04-25
Lead Sponsor
GE Healthcare
Target Recruit Count
66
Registration Number
NCT00348608

A Study of Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain

Not Applicable
Completed
Conditions
Coronary Artery Disease
Interventions
Device: 64 Channel VCT
First Posted Date
2006-07-04
Last Posted Date
2019-04-29
Lead Sponsor
GE Healthcare
Target Recruit Count
245
Registration Number
NCT00348569
Locations
πŸ‡ΊπŸ‡Έ

Robert Centofanti, MS, Princeton, New Jersey, United States

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

Phase 3
Terminated
Conditions
Coronary Artery Disease
Interventions
Drug: iodixanol
First Posted Date
2006-06-09
Last Posted Date
2019-04-25
Lead Sponsor
GE Healthcare
Target Recruit Count
89
Registration Number
NCT00335335

Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography

First Posted Date
2006-06-08
Last Posted Date
2019-04-29
Lead Sponsor
GE Healthcare
Registration Number
NCT00335101
Locations
πŸ‡©πŸ‡ͺ

GE Healthcare, Munich, Germany

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

First Posted Date
2005-09-21
Last Posted Date
2014-10-17
Lead Sponsor
GE Healthcare
Target Recruit Count
656
Registration Number
NCT00209417
Locations
πŸ‡¬πŸ‡§

GE Healthcare, Amersham, United Kingdom

A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-iliac Arteries While Using Gadodiamide

First Posted Date
2005-09-21
Last Posted Date
2019-04-25
Lead Sponsor
GE Healthcare
Target Recruit Count
407
Registration Number
NCT00209443
Locations
πŸ‡©πŸ‡ͺ

Amersham Buchler GmbH & Co. KG, Ismaning, Germany

Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia

First Posted Date
2005-09-21
Last Posted Date
2007-05-16
Lead Sponsor
GE Healthcare
Target Recruit Count
326
Registration Number
NCT00209456
Locations
πŸ‡©πŸ‡ͺ

Amersham Buchler GmbH Co. KG, Ismaning, Germany

A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide

Phase 3
Completed
Conditions
Renal Artery Stenosis
Interventions
Drug: Gadodiamide Injection
First Posted Date
2005-09-21
Last Posted Date
2019-04-25
Lead Sponsor
GE Healthcare
Target Recruit Count
395
Registration Number
NCT00209391
Locations
πŸ‡©πŸ‡ͺ

Amersham Buchler GmbH & Co. KG, Ismaning, Germany

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography

Phase 4
Completed
Conditions
Coronary Artery Disease
Renal Impairment
First Posted Date
2005-09-21
Last Posted Date
2007-10-31
Lead Sponsor
GE Healthcare
Target Recruit Count
408
Registration Number
NCT00209430
Locations
πŸ‡ΈπŸ‡ͺ

Amersham Health S.A, Solna, Sweden

Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)

Phase 4
Completed
Conditions
Coronary Artery Disease
First Posted Date
2005-09-21
Last Posted Date
2007-10-31
Lead Sponsor
GE Healthcare
Target Recruit Count
50
Registration Number
NCT00209404
Locations
πŸ‡«πŸ‡·

Amersham Health S.A., Velizy Cedex, France

Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy